Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses
Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses

Brain and Central Nervous System Tumors

Neuroblastoma

Sarcoma

Unspecified Childhood Solid Tumor, Protocol Specific

60-230mg/m2 weekly during each 28 day course, for up to 12 courses

Temsirolimus

All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses

Valproic Acid

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Carolina Healthcare System

Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors

The planned starting dose of Temsirolimus is 60mg/M2. The traditional 3+3 design will be used, where the MTD is defined as the dose with the probability of a DLT of 0.20

Each patient will be classified according to their "best response". Best response is determined from the sequence of the objective statuses as described in RECIST 1.1

If the patient's disease has not progressed at the time protocol-directed therapy is complete, any tumor assessments available during the follow-up period (up to 3 years) will be evaluated using RECSIT 1.1

Blood will be drawn prior to, 30 minutes, 1hr, 2hr, 5hr, 24hr after completion of doses 1 and 5. Levels of Temsirolimus will be measured using validated liquid chromatography and tandem mass spectroscopic methods

UNC Lineberger Comprehensive Cancer Center

National Cancer Institute (NCI)

Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma

Soft Tissue Sarcoma

Locally Advanced Sarcoma

Unresectable Sarcoma

Metastatic Sarcoma

Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid

University of Iowa Hospitals and Clinics

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Dose-limiting toxicities per CTCAE 4.0; grade 4 hematologic toxicity; grade 3 or 4 hepatotoxicity.

Mohammed M Milhem

Clinical Associate Professor

Genentech, Inc.

valproic acid

Jonsson Comprehensive Cancer Center at UCLA

Veterans Affairs Medical Center - San Diego

UCSF Comprehensive Cancer Center

Georgia Cancer Center for Excellence at Grady Memorial Hospital

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Beth Israel Deaconess Medical Center

Siteman Cancer Center at Barnes-Jewish Hospital

Albert Einstein Cancer Center at Albert Einstein College of Medicine

Memorial Sloan-Kettering Cancer Center

Case Comprehensive Cancer Center

Joan Karnell Cancer Center at Pennsylvania Hospital

Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center

Valproic Acid in Treating Patients With Kaposi's Sarcoma

A Pilot Trial Of Valproic Acid In Patients With Kaposi's Sarcoma

AIDS Malignancy Consortium

The Emmes Company, LLC

sarcoma

valproic acid/sarcoma

Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

Valproic Acid in Treating Patients With Kaposi's Sarcoma

O mais completo banco de dados de ervas medicinais apoiado pela ciência